Clinical implications of BRAF mutation in thyroid carcinoma.
about
Novel approaches in anaplastic thyroid cancer therapySorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational statusBRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.B-Raf mutation and papillary thyroid carcinoma patients.RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancerRole of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules.Differentiated thyroid tumors: surgical indications.Targeted molecular therapies in thyroid carcinoma.Targeting histone deacetylase in thyroid cancer.VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma.PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.Diagnostic Accuracy of Contrast-Enhanced Ultrasound Enhancement Patterns for Thyroid NodulesNucleophosmin delocalization in thyroid tumour cells.Diagnostic and prognostic markers in differentiated thyroid cancer.Somatic amplifications and deletions in genome of papillary thyroid carcinomas.PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.MicroRNAs as Biomarkers in Thyroid Carcinoma.PDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis.The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification.Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
P2860
Q34458018-D8922126-C02E-42A5-896D-18C4E503BEDDQ35603183-BD1D2AD7-5123-4D55-8A60-A2F506593C9AQ36654999-6D155C1A-273D-4F95-8BBE-D95B65EDF3ABQ36741221-8DF0EDC4-5E65-4918-800C-95C6849A4AA2Q37087082-B13AAA4E-3584-4034-9336-DD95CABA7D72Q37270522-24005362-3EBA-4AC2-985D-F5476C934BF3Q37431090-EE30FF21-B1E4-495C-BBE4-451194267A3EQ37560570-EA49A9EC-D79E-4FE0-8EF9-7F75CD234D37Q37686162-944EDEB5-16FC-4263-A19C-01C66BE3D1E3Q38066990-47B1F97D-A172-44D8-8D23-A9FCE67923F1Q38426776-6BEE91C8-B126-4094-AB76-C003447B1AC0Q38566267-C929F3DA-9347-4317-85C4-AA6A0A532064Q38682192-E8C9DDD1-62C6-4273-8139-654AB60B35B6Q38891514-8A4BDD63-992B-4C64-8005-368E3F4ABF3EQ39131867-2E7FED0D-0D0A-4D1A-BEFD-40EC576517F9Q39603964-CE70A107-4A3E-4873-9A91-0E7F4758E92CQ40819992-9476D272-4B63-4620-87C8-19AD4EC9EC7CQ41088523-BD65CB96-8D24-411C-8BA9-D67C1EF2320DQ41814211-5CB938DB-50B3-4C99-8B96-16E25C5A4E58Q42361202-553844D0-EDA2-4FBA-8F45-39B8040AF87CQ43268349-2669B25A-6D14-4C63-9379-3D6C9AB929EAQ43740818-1CBD2568-647E-4481-8963-FB87D1B9B1DDQ44425656-9D91A131-BEF3-4718-9466-EAF9A5C81CDCQ44572478-9EBD6318-5024-49E2-9ADB-64020C9B3169Q44591315-E9A05892-63BA-4CAF-BF5A-6FEC2637ECD9Q52845108-F8918E27-21E5-49BE-B9A5-A873FCA975DEQ55058474-A218A6B0-5F5E-469E-9572-C65EF2704880
P2860
Clinical implications of BRAF mutation in thyroid carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical implications of BRAF mutation in thyroid carcinoma.
@en
Clinical implications of BRAF mutation in thyroid carcinoma.
@nl
type
label
Clinical implications of BRAF mutation in thyroid carcinoma.
@en
Clinical implications of BRAF mutation in thyroid carcinoma.
@nl
prefLabel
Clinical implications of BRAF mutation in thyroid carcinoma.
@en
Clinical implications of BRAF mutation in thyroid carcinoma.
@nl
P2093
P1476
Clinical implications of BRAF mutation in thyroid carcinoma
@en
P2093
Diego Russo
Efisio Puxeddu
Nicola Avenia
Sebastiano Filetti
P304
P356
10.1016/J.TEM.2007.12.003
P577
2008-03-11T00:00:00Z